Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07082920 · ClinicalTrials.gov registry record · Phase 1

A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

A Phase 1 study of Prostatic Neoplasms, sponsored by Janssen Research & Development.

Recruiting
Registry status
Phase 1
Development phase
140
Enrollment target
6
Study locations

NCT07082920 is a Phase 1 study of Prostatic Neoplasms that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 140 participants, below the 512-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (73% lower). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07082920, a Phase 1 study of Prostatic Neoplasms, is actively recruiting participants, sponsored by Janssen Research & Development.

RECRUITING
Registry status
Phase 1
Development phase
140 participants
Enrollment target
6
Study locations

Study Summary

The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of JNJ-78278343 in combination with JNJ-95298177 in Part 1 (Dose confirmation) of the study and to determine how safe and tolerable the RP2CD is for treatment of participants with metastatic castration-resistant prostate cancer (mCRPC; a stage of prostate cancer where the cancer has spread beyond the prostate and is resistant to hormonal therapy) in Part 2 (Dose expansion) of study.

Conditions Studied

Prostatic Neoplasms

Interventions

  • DRUG JNJ-78278343
  • DRUG JNJ-95298177

Study Locations (6)

Other

  • The Christie Nhs Foundation Trust - Manchester
  • Royal Marsden Hospital (Sutton) - Sutton

Florida

  • Florida Cancer Specialists - Sarasota

New York

  • Columbia University Medical Center - New York

Ohio

  • University Hospitals Cleveland Medical Center - Cleveland

Washington

  • Fred Hutchinson Cancer Center - Seattle

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2025-07-07
Est. Completion 2027-03-01
Phase Phase 1

Sponsor

Janssen Research & Development

593 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07082920

The ClinicalTrials.gov registry entry for NCT07082920 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 512-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (73% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostatic Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which JNJ-78278343 is the first listed.

NCT07082920 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Other, Florida, New York.

Frequently Asked Questions

What is clinical trial NCT07082920 about?

NCT07082920 is a clinical study titled "A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer". The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of JNJ-78278343 in combination with JNJ-95298177 in Part 1 (Dose confirmation) of the study and to determine how safe and tolerable the RP2CD is for treatment of participants with metastatic castration-resistan...

What is the current status of trial NCT07082920?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2025-07-07. Estimated completion is 2027-03-01.

What conditions does trial NCT07082920 study?

This clinical trial studies the following conditions: Prostatic Neoplasms.

What interventions are being tested in trial NCT07082920?

The interventions under investigation include: JNJ-78278343 (DRUG), JNJ-95298177 (DRUG).

Who is sponsoring clinical trial NCT07082920?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07082920 being conducted?

This trial has 6 study locations across Florida, New York, Ohio, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostatic Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostatic Neoplasms

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.